EMA and FDA green-light MoonLake to advance IL-17 inhibitor

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

Submitted by admin on February 28, 2024 - 9:38pm
Source: 
Clinical Trials Arena
News Tags: 
MoonLake Immunotherapeutics
sonelokimab
FDA
EMA
hidradenitis suppurativa
Headline: 
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
snippet: 

The Phase III VELA program will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.

Do Not Allow Advertisers to Use My Personal information